Lactation during and after Breast Cancer

Area of Science:

• Oncology
• Pediatrics
• Lactation

Background:

• Breastfeeding is crucial for infant development and the maternal-infant bond.
• Maternal medications, including cancer therapies, can transfer into breast milk, posing risks to the neonate.
• Limited data exists on the safety of breastfeeding during and after various cancer treatments.

Purpose of the Study:

• To provide guidance on breastfeeding for mothers undergoing or who have undergone cancer treatment.
• To highlight the potential risks of drug transfer through breast milk during active cancer therapy.
• To emphasize the benefits and feasibility of breastfeeding post-cancer treatment.

Main Methods:

• Review of current literature on drug transfer in breast milk.
• Analysis of safety data for chemotherapy, hormonal therapy, targeted agents, and monoclonal antibodies during lactation.
• Evaluation of outcomes for mothers and infants in relation to breastfeeding after cancer treatment.

Main Results:

• Breastfeeding should be discontinued during active cancer treatment, including chemotherapy, hormonal therapy, targeted agents, and monoclonal antibodies.
• Maternal prognosis is not worsened by subsequent pregnancies after cancer diagnosis.
• Post-treatment, breastfeeding is generally advisable, though radiation may affect milk production in the affected breast.

Conclusions:

• A cautious approach to breastfeeding is essential during maternal anticancer treatment.
• Breastfeeding cessation is recommended during active cancer therapies.
• Breastfeeding can be resumed and is encouraged after cancer treatment completion, with considerations for localized effects like radiation.